Interpretation of Clinical Practice Guidelines for Management of Kidney Injury During Anticancer Drug Therapy 2022 (Ⅱ): evaluation of kidney function in patients undergoing anticancer drug therapy (Part 1)
10.3760/cma.j.cn114015-20240407-00234
- VernacularTitle:《抗肿瘤药物治疗期间肾损伤管理临床实践指南（2022）》解读（二）：抗肿瘤药物治疗患者的肾功能评估（第1部分）
- Author:
Yina WANG
1
;
Li ZUO
1
;
Yu YAN
1
Author Information
1. 北京大学人民医院肾内科，北京 100044
- Publication Type:Journal Article
- Keywords:
Antineoplastic agents;
Acute kidney injury;
Renal insufficiency;
Guideline
- From:
Adverse Drug Reactions Journal
2024;26(6):321-325
- CountryChina
- Language:Chinese
-
Abstract:
Anticancer drugs play an important role in the treatment for malignant tumors. The kidney function of patients has an important impact on the choice of anticancer drugs, the safety during treatments, and the prognosis of patients. All cancer patients should undergo comprehensive kidney function assessment before using anticancer drugs, so as to formulate an individualized anticancer regimen. The Japanese Society of Nephrology, Japan Society of Clinical Oncology, Japanese Society of Medical Oncology, and Japanese Society of Nephrology and Pharmacotherapy have formulated the Clinical Practice Guidelines for Management of Kidney Injury During Anticancer Drug Therapy 2022 and made special discussions and suggestions on the evaluation of kidney function of tumor patients before anticancer drug treatment. This article interprets this part in order to made a more comprehensive understanding on the occurrence and risk factors of kidney disease in cancer patients in the clinic. Paying attention to the kidney function assessment of cancer patients before anticancer drug treatment and mastering the correct assessment methods can help improve the kidney safety of cancer patients during treatments.
